Research programme: selective nicotinic acetylcholine receptor agonists - Suven Life Sciences

Drug Profile

Research programme: selective nicotinic acetylcholine receptor agonists - Suven Life Sciences

Alternative Names: SUVN F90101; SUVN-F91201

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class Neuroprotectants
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic disorders
  • No development reported Alzheimer's disease

Most Recent Events

  • 20 Feb 2018 Suven Life Sciences has patent protection for alpha-4-beta-2 compounds in South Korea and India
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in India
  • 29 Dec 2015 Suven Life Sciences has patent protection for alpha-4-beta-2 compounds for the treatment of major depressive disorder in Europe and Macau
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top